Access DB# 79992

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: (STIC) Lynda Guo Examiner #: 79756 Date: 11/12/02
Art Unit: 1651 Phone Number 30~~6~~ 605-1200 Serial Number: 09/979,533
Mail Box and Bldg/Room Location: CM1-11B01 Results Format Preferred (circle): PAPER DISK E-MAIL
office: 11A46

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Method for increasing the propionate in the gastro-intestinal tract

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan please!

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location: _____
Date Searcher Picked Up: 11/14/02
Date Completed: 11/14/02
Searcher Prep & Review Time: _____
Clerical Prep Time: 15
Online Time: 195

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) 1
Bibliographic ✓
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN ✓
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

PTO-1590 (8-01)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> d his

     (FILE 'HOME' ENTERED AT 07:28:54 ON 14 NOV 2002)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:29:05 ON 14 NOV 2002
               E PROPIONIC ACID/CN
L1             1 S E3
               E PROPIONATE/CN
L2             1 S E3
               E DEXTRAN/CN
L3             1 S E3
L4             2 S L1,L2
               SEL RN
L5          1416 S E1-E2/CRN
L6           929 S L5 NOT (MNS OR MXS OR IDS OR PMS OR AYS OR CCS)/CI
L7           530 S L6 NOT COMPD
L8           331 S L7 NOT SALT
L9           199 S L7 NOT L8
L10           15 S L9 AND NR>=1
L11          184 S L9 NOT L10
L12          186 S L4,L11
               SEL RN L3
L13          931 S E3/CRN
L14         1132 S DEXTRAN
L15         1134 S L13,L14
L16         1133 S L15 NOT L3
               E INULIN/CN
L17            1 S E3
               E FRUCTOSE/CN
L18            2 S E3
L19            1 S L-FRUCTOSE/CN
               E GALACTOSE/CN
L20            2 S E3
L21            1 S L-GALACTOSE/CN
               E XYLOSE/CN
L22            2 S E3
L23            1 S L-XYLOSE/CN

     FILE 'HCAPLUS' ENTERED AT 07:47:22 ON 14 NOV 2002
L24        19794 S L4
L25         2929 S L11
L26        68956 S PROPIONIC ACID OR PROPIONATE
L27         5679 S PROPANOIC ACID
L28        78352 S L24-L27
L29        11735 S L3
L30         7546 S L16
L31        30359 S DEXTRAN
L32        31947 S ?DEXTRAN?
L33        33493 S L29-L32
L34          158 S L28 AND L33

     FILE 'REGISTRY' ENTERED AT 07:50:44 ON 14 NOV 2002
L35            1 S CHOLESTEROL/CN

     FILE 'HCAPLUS' ENTERED AT 07:50:48 ON 14 NOV 2002
L36        85119 S L35
L37       153391 S ?CHOLESTER?
L38        10311 S HYPERLIPID? OR HYPERLIPEM? OR HYPERLIPAEM?
L39        28640 S TRIGLYER? OR VLDL OR HDL OR LIPOPROTEIN(L)(VLD OR HD OR VERY

     FILE 'REGISTRY' ENTERED AT 07:53:24 ON 14 NOV 2002
L40            1 S INSULIN/CN
```

```
L41         6388 S INSULIN NOT L40

     FILE 'HCAPLUS' ENTERED AT 07:53:33 ON 14 NOV 2002
L42       101061 S L40 OR L41
L43       148034 S ?INSULIN?

     FILE 'REGISTRY' ENTERED AT 07:53:52 ON 14 NOV 2002
L44            2 S GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 07:53:58 ON 14 NOV 2002
L45       133720 S L44
L46       342761 S GLUCOSE
L47           35 S L34 AND L36-L39,L42,L43,L45,L46
L48        33393 S LIPOPROTEIN(L)(VERY ()(LOW DENSITY OR LOW DEN OR L DENSITY OR
L49            1 S L34 AND L48
L50           35 S L47,L49
L51            2 S L3 (L) FFD/RL AND L50
L52            2 S L50 AND NUTRI?/SC,SX
L53           12 S L50 AND (L17-L23 OR INULIN OR ?FRUCTO? OR ?GALACTO? OR ?XYLO?
                 E SACCHARIDE/CT
                 E E4+ALL
L54         1628 S E1
                 E E3+ALL
L55         7563 S E3
                 E E4+ALL
                 E E4+ALL
L56        26460 S E4,E3,E18,E37,E38,E64
                 E E5+ALL
                 E E5+ALL
L57        39306 S E3
L58           12 S L50 AND L54-L57
L59           20 S L51-L53,L58
L60            3 S L59 AND FATTY ACID
L61            3 S L59 AND LIPID
L62            4 S L60,L61
                 SEL DN AN 2 3
L63            2 S L62 AND E1-E6
L64           31 S L50 NOT L62
                 SEL DN AN 4 31
L65            2 S L64 AND E7-E12
L66            4 S L63,L65 AND L24-L34,L36-L39,L42,L43,L45-L65
L67            3 S L34 AND TRIGLYCER?
L68            1 S L67 AND GASTRO INTESTINAL TRACT
L69            4 S L66,L68
                 E JANN A/AU
L70           13 S E3,E5
                 E ARRIGONI E/AU
L71          117 S E3,E8,E9
                 E ROCHAT F/AU
L72           19 S E3-E5,E7
                 E SCHMID D/AU
L73          160 S E3-E15
                 E BAUCHE A/AU
L74            4 S E3,E5
                 E NESTLE/PA,CS
L75         2322 S E3,E4
L76         2325 S NESTLE?/PA,CS
L77            1 S L50 AND L70-L76
L78            4 S L69,L77
L79         4165 S L28 AND (GASTROINTESTIN? OR GASTRO INTESTIN? OR ?INTESTIN? OR
                 E GASTROINTESTIN/CT
                 E E30+ALL
                 E E2+ALL
```

```
L80       551727 S E3+NT
L81         4420 S E102+NT OR E106+NT
                 E GASTROINTESTIN/CT
                 E E9+ALL
L82         3886 S E2
                 E ANTICHOLESTEROL/CT
                 E E4+ALL
                 E E2+ALL
L83         8108 S E5,E6,E4+NT
L84         3567 S L28 AND L80-L83
L85         6169 S L79,L84
L86          319 S L85 AND CARBOHYDRATE?/SC,SX,CW
L87         2153 S L28 AND L36-L39,L42,L43
L88           74 S L87 AND CARBOHYDRATE?/SC,SX,CW
L89           12 S L86,L87 AND L33
L90            3 S L89 AND L78
L91            9 S L89 NOT L90
L92           34 S L85,L87 AND L33
L93           19 S L92 NOT L50
                 SEL DN AN 12
L94            1 S E1-E3 AND L93
L95            5 S L78,L90,L94
                 SEL HIT RN

    FILE 'REGISTRY' ENTERED AT 08:34:16 ON 14 NOV 2002
L96            8 S E4-E11

=> fil reg
FILE 'REGISTRY' ENTERED AT 08:34:42 ON 14 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 NOV 2002  HIGHEST RN 473382-28-4
DICTIONARY FILE UPDATES:  12 NOV 2002  HIGHEST RN 473382-28-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l96

L96  ANSWER 1 OF 8  REGISTRY  COPYRIGHT 2002 ACS
RN   9042-14-2  REGISTRY
CN   Dextran, hydrogen sulfate (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Dextran polysulfate
CN   Dextran sulfate
CN   Dextran sulfate 500
CN   Dextran sulfate 5000
CN   Dextran sulfuric acid
CN   Dextran sulphate
```

CN MDS-Kowa
CN NSC 620255
CN PF 51
CN PF 51 (carbohydrate)
CN Polydextran sulfate
CN Polyglucin, sulfate
CN Sulfopolyglucin
CN T 500
DR 9057-27-6, 9063-02-9, 50935-34-7, 37271-05-9, 73075-68-0, 191288-77-4
MF H2 O4 S . x Unspecified
CI COM
PCT Manual registration, Polyother, Polyother only
LC STN Files: ADISINSIGHT, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 9004-54-0
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S



2477 REFERENCES IN FILE CA (1962 TO DATE)
165 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2482 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299974

REFERENCE 2: 137:293552

REFERENCE 3: 137:293522

REFERENCE 4: 137:293290

REFERENCE 5: 137:289051

REFERENCE 6: 137:284401

REFERENCE 7: 137:284290

REFERENCE 8: 137:276876

REFERENCE 9: 137:243046

REFERENCE 10: 137:241444

L96 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **9005-80-5** REGISTRY
CN Inulin (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Alant starch
CN Alantin
CN Dahlin
CN Fibruline
CN Fibruline Instant
CN Fibruline LC
CN Fibruline Long Chain
CN Frutafit
CN Frutafit HD
CN Frutafit IQ
CN Inulin IQ
CN Inutec N 10GR
CN Raftiline
CN Raftiline GR
CN Raftiline HP
CN Raftiline LS
CN Raftiline ST
CN Sinantrin
CN Synantherin
CN Synanthrin
CN Synantrin
DR 189444-25-5
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
2463 REFERENCES IN FILE CA (1962 TO DATE)
187 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2469 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299965

REFERENCE 2: 137:299752

REFERENCE 3: 137:288433

REFERENCE 4: 137:283981

REFERENCE 5: 137:278427

REFERENCE 6: 137:278265

REFERENCE 7: 137:278121

REFERENCE 8: 137:272957

REFERENCE 9: 137:268311

REFERENCE 10: 137:268175

L96 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **9004-54-0** REGISTRY
CN Dextran (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Dextrans (8CI)
OTHER NAMES:
CN .alpha.-Dextran
CN 58: PN: WO0185782 FIGURE: 18 claimed sequence
CN CDC-H
CN DEX 500
CN Dextran 1.5
CN Dextran 10
CN Dextran 1000
CN Dextran 110
CN Dextran 15
CN Dextran 150
CN Dextran 2000
CN Dextran 250
CN Dextran 3000
CN Dextran 40
CN Dextran 45
CN Dextran 500
CN Dextran 60
CN Dextran 70
CN Dextran 75
CN Dextran B 512
CN Dextran B1355
CN Dextran D 10
CN Dextran PL 1S
CN Dextran PT 25
CN Dextran PVD
CN Dextran RMI
CN Dextran T 10
CN Dextran T 110
CN Dextran T 150
CN Dextran T 20
CN Dextran T 2000
CN Dextran T 500
CN Dextran T 70
CN Dextranen
CN Dextraven
CN Eudextran
CN Expandex
CN Gentran
CN Hemodex
CN Hyscon
CN Hyskon
CN Infucoll
CN Intrader
CN Intradex
CN LMD
CN LMWD
CN Longasteril 70
CN LU 122
CN LVD
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 12626-85-6, 9013-80-3, 9044-66-0, 11104-36-2, 11121-03-2, 37224-17-2, 86280-85-5
MF Unspecified
CI PMS, COM, MAN

PCT Manual registration, Polyother, Polyother only
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
11709 REFERENCES IN FILE CA (1962 TO DATE)
2200 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11737 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299981

REFERENCE 2: 137:299723

REFERENCE 3: 137:299668

REFERENCE 4: 137:296727

REFERENCE 5: 137:296464

REFERENCE 6: 137:296463

REFERENCE 7: 137:296246

REFERENCE 8: 137:296138

REFERENCE 9: 137:295451

REFERENCE 10: 137:293545

L96 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **9004-10-8** REGISTRY
CN Insulin (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Actrapid
CN Actrapid HM
CN Actrapid MC
CN Decurvon
CN Dermulin
CN Endopancrine
CN Exubera
CN HMR 4006
CN Iletin
CN Insular
CN Insulin Injection
CN Insulyl
CN Intesulin B
CN Iszilin
CN Musulin
DR 8049-67-0, 8049-95-4, 9004-12-0, 9045-63-0, 9045-65-2, 9045-66-3, 9045-67-4, 9066-39-1, 9066-40-4, 11081-38-2, 57126-42-8, 37243-75-7, 37294-43-2, 69090-47-7, 88026-11-3, 88026-12-4
MF Unspecified
CI PMS, COM, MAN
PCT Manual registration
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,

CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
81080 REFERENCES IN FILE CA (1962 TO DATE)
1487 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
81116 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:299964

REFERENCE 2: 137:299963

REFERENCE 3: 137:299954

REFERENCE 4: 137:299914

REFERENCE 5: 137:299885

REFERENCE 6: 137:299873

REFERENCE 7: 137:295256

REFERENCE 8: 137:294183

REFERENCE 9: 137:294178

REFERENCE 10: 137:294164

L96 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **79-09-4** REGISTRY
CN Propanoic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propionic acid (6CI, 8CI)
OTHER NAMES:
CN Adofeed
CN Antischim B
CN Carboxyethane
CN Ethanecarboxylic acid
CN Ethylformic acid
CN Luprosil
CN Metacetonic acid
CN Methylacetic acid
CN MonoProp
CN Propcorn
CN Propkorn
CN Prozoin
CN Pseudoacetic acid
CN Toxi-Check
FS 3D CONCORD
MF C3 H6 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB

(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19350 REFERENCES IN FILE CA (1962 TO DATE)
909 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
19388 REFERENCES IN FILE CAPLUS (1962 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:302992

REFERENCE 2: 137:300511

REFERENCE 3: 137:299932

REFERENCE 4: 137:299395

REFERENCE 5: 137:299075

REFERENCE 6: 137:299064

REFERENCE 7: 137:298879

REFERENCE 8: 137:297042

REFERENCE 9: 137:296517

REFERENCE 10: 137:296472

L96 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **59-23-4** REGISTRY
CN D-Galactose (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Galactose, D- (8CI)
OTHER NAMES:
CN (+)-Galactose
CN D-(+)-Galactose
CN Galactose
FS STEREOSEARCH
DR 147-76-2, 3812-56-4, 400876-94-0
MF C6 H12 O6
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16669 REFERENCES IN FILE CA (1962 TO DATE)
695 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16701 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:300027

REFERENCE 2: 137:299955

REFERENCE 3: 137:296477

REFERENCE 4: 137:295220

REFERENCE 5: 137:295189

REFERENCE 6: 137:294430

REFERENCE 7: 137:294159

REFERENCE 8: 137:293919

REFERENCE 9: 137:293899

REFERENCE 10: 137:293665

L96 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **57-88-5** REGISTRY
CN Cholest-5-en-3-ol (3.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cholesterol (8CI)
OTHER NAMES:
CN (-)-Cholesterol
CN .DELTA.5-Cholesten-3.beta.-ol
CN 3.beta.-Hydroxycholest-5-ene
CN 5:6-Cholesten-3.beta.-ol
CN Cholest-5-en-3.beta.-ol
CN Cholesterin
CN Cholesteryl alcohol
CN Dythol
CN Lidinit
CN Lidinite
CN Provitamin D
FS STEREOSEARCH
DR 209124-38-9, 218965-24-3, 378185-03-6
MF C27 H46 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2,

USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

85113 REFERENCES IN FILE CA (1962 TO DATE)
8308 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
85183 REFERENCES IN FILE CAPLUS (1962 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:300027

REFERENCE 2: 137:299891

REFERENCE 3: 137:299877

REFERENCE 4: 137:299733

REFERENCE 5: 137:299732

REFERENCE 6: 137:299715

REFERENCE 7: 137:299706

REFERENCE 8: 137:299702

REFERENCE 9: 137:299696

REFERENCE 10: 137:299674

L96 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **50-99-7** REGISTRY
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Glucose
CN Anhydrous dextrose
CN Cartose
CN Cerelose
CN Cerelose 2001
CN Corn sugar
CN D(+)-Glucose
CN Dextropur
CN Dextrose
CN Dextrosol
CN Glucolin

CN Glucose
CN Glucosteril
CN Goldsugar
CN Grape sugar
CN Maxim Energy Gel
CN Roferose ST
CN Staleydex 111
CN Staleydex 333
CN Sugar, grape
CN Tabfine 097(HS)
CN Vadex
FS STEREOSEARCH
DR 8012-24-6, 8030-23-7, 162222-91-5, 165659-51-8, 50933-92-1, 80206-31-1
MF C6 H12 O6
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

133561 REFERENCES IN FILE CA (1962 TO DATE)
2016 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
133673 REFERENCES IN FILE CAPLUS (1962 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:303955

REFERENCE 2: 137:301291

REFERENCE 3: 137:301282

REFERENCE 4: 137:300521

REFERENCE 5: 137:300332

REFERENCE 6: 137:300027

REFERENCE 7: 137:299968

REFERENCE 8: 137:299955

REFERENCE 9: 137:299937

REFERENCE 10: 137:299913

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:34:58 ON 14 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Nov 2002  VOL 137 ISS 20
FILE LAST UPDATED: 13 Nov 2002  (20021113/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> d all tot l95 hitstr

L95  ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2002 ACS
AN   2002:293417  HCAPLUS
DN   136:315003
TI   Particulate bulking agents for medicinal aerosol formulations
IN   Jinks, Philip A.; McKenzie, Lesley; Lister, James T.
PA   3M Innovative Properties Company, USA
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K009-00
CC   63-6 (Pharmaceuticals)
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2002030394     A2    20020418      WO 2001-US30575  20011001
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL,
             TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
             KG, KZ, MD, RU
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002011311     A5    20020422      AU 2002-11311    20011001
PRAI GB 2000-24711     A     20001009
     GB 2001-22512     A     20010918
     WO 2001-US30575   W     20011001
AB   Use of particulate bulking agents having an extremely small mass median
```

diam. of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, org. and inorg. salts, urea, and propyliodone. .alpha.-Lactose monohydrate was micronized and dispersed in anhyd. ethanol and homogenized.

ST pharmaceutical aerosol bulking agent

IT Drug delivery systems
(aerosols; particulate bulking agents for medicinal aerosol formulations)

IT Alkanes, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluoro; particulate bulking agents for medicinal aerosol formulations)

IT Polyesters, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; particulate bulking agents for medicinal aerosol formulations)

IT Particle size
Propellants (sprays and foams)
Surfactants
(particulate bulking agents for medicinal aerosol formulations)

IT 9004-34-6, Cellulose, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified; particulate bulking agents for medicinal aerosol formulations)

IT 64044-51-5, Lactose monohydrate
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 50-81-7, Ascorbic acid, biological studies **50-99-7**, D-**Glucose**, biological studies 56-40-6, Glycine, biological studies 57-13-6, Urea, biological studies 57-50-1, Sucrose, biological studies **59-23-4**, D-**Galactose**, biological studies 63-42-3, Lactose 69-79-4, Maltose 112-80-1, Oleic acid, biological studies 128-44-9, Sodium saccharin 302-72-7, Alanine 431-89-0, HFA 227 471-34-1, Calcium carbonate, biological studies 587-61-1, Propyliodone 811-97-2, HFA 134a 814-80-2, Calcium lactate 6138-23-4, .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl, dihydrate 7647-14-5, Sodium chloride, biological studies 9004-53-9, Dextrin **9004-54-0**, **Dextran**, biological studies 9005-25-8, Starch, biological studies 14475-11-7, Sodium tartrate 17629-30-0, D-Raffinose pentahydrate 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Polylactic acid 26266-58-0, Sorbitan trioleate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 43229-80-7, Formoterol fumarate 51022-70-9, Salbutamol sulfate
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT 60205-81-4, Ipratropium 72332-33-3, Procaterol 73573-87-2, Formoterol 80474-14-2, Fluticasone **propionate** 89365-50-4, Salmeterol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)

IT **50-99-7**, D-**Glucose**, biological studies **59-23-4**, D-**Galactose**, biological studies **9004-54-0**, **Dextran**, biological studies

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particulate bulking agents for medicinal aerosol formulations)
RN 50-99-7 HCAPLUS
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59-23-4 HCAPLUS
CN D-Galactose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN **2001:833060** HCAPLUS
DN **135:376741**
TI Stable metal ion-**lipid** powdered pharmaceutical compositions
IN Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E.
PA Alliance Pharmaceutical Corp., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-00
CC 63-6 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085137	A2	20011115	WO 2001-US14824	20010508
	WO 2001085137	A3	20020418		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-568818 A 20000510

AB Microparticle compns. comprising metal ion-**lipid** complexes for drug delivery are described including methods of making the microparticle compns. and methods of treating certain conditions and disease states by administering the microparticle compns. The metal ion-**lipid** complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compns. of the present invention have superior stability to other microparticle compns. resulting in a microparticle compn. with longer shelf life and improved dispersibility. The microparticle compns. of the present invention have a transition temp. (Tm) of at least 20.degree. above the recommended storage temp. (Tst) for drug delivery. An aq. prepn. was prepd. by mixing two prepns., A and B, immediately prior to spray drying. The prepn. A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluorooctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The prepn. B contained 0.162 g CaCl2.2H20 and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl2.2H20 wt. ratio of about 80:10:10. The mean vol. aerodynamic particle size of the dry powder was approx. 4.1 .mu.m.

ST metal phospholipid powder pharmaceutical

IT Drug delivery systems
(aerosols; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(block; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Ribozymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deoxy; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dinucleotides; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(egg yolk; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Glycerophospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Anemia (disease)
(inhibitors; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(injections, i.m.; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(injections, i.p.; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(injections, i.v.; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(injections, s.c.; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(intratracheal; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactide; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT **Fatty acids**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metal salts; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Drug delivery systems
(microparticles; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Drug delivery systems
(nasal; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Drug delivery systems
(ophthalmic; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Carotenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxy; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenolic; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Phospholipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Phenolic resins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Drug delivery systems
(powders, inhalants; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, hydrogenated; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya; stable metal ion-**lipid** powd. pharmaceutical compns.)
IT Allergy inhibitors
Analgesics
Anti-inflammatory agents
Antibiotics
Antihistamines
Antimigraine agents
Antioxidants
Antitumor agents
Bronchodilators
Cardiovascular agents
Cholinergic antagonists
Density
Fungicides
Gene therapy
Imaging agents
Leukotriene antagonists
Particle size distribution
Plasticizers
Pulmonary surfactant
Tuberculostatics
Wetting agents
(stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Actinides
Agglutinins and Lectins
Albumins, biological studies
Caseins, biological studies
Enzymes, biological studies
Immunoglobulins
Lipids, biological studies
Ovalbumin
Peptides, biological studies
Phospholipids, biological studies
Polyesters, biological studies
Polyoxyalkylenes, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Rare earth metals, biological studies
Ribozymes
Salts, biological studies
Steroids, biological studies
Tocopherols
Transition metals, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(topical; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT Drug delivery systems
(vaginal; stable metal ion-**lipid** powd. pharmaceutical compns.)

IT 50-02-2, Dexamethasone 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 74-55-5, Ethambutol 76-25-5, Triamcinolone acetonide 99-20-7, Trehalose 110-01-0, THT 128-37-0, BHT, biological studies 471-34-1, Calcium carbonate, biological studies 1403-66-3, Gentamicin 1405-41-0, Gentamicin sulfate 2644-64-6, DPPC 3458-28-4, Mannose 4539-70-2, DSPC 5534-09-8, Beclomethasone dipropionate 7429-90-5, Aluminum, biological studies 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7786-30-3, Magnesium chloride (MgCl2), biological studies 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Poly(acrylic acid) 9003-01-4D, Poly(acrylic acid), salts 9003-39-8, PVP **9004-10-8**, **Insulin**, biological studies 9004-32-4, Carboxymethyl cellulose 9004-34-6D, Cellulose, esters, biological studies **9004-54-0**, **Dextran**, biological studies 9005-25-8, Starch, biological studies 9005-25-8D, Starch, derivs., biological studies 9005-27-0, Hydroxyethyl starch **9005-80-5**, **Inulin** 9012-76-4, Chitosan 9012-76-4D, Chitosan, derivs. **9042-14-2**, **Dextran** sulfate 9072-56-4, Starch ethyl ether 10043-52-4, Calcium chloride (CaCl2), biological studies 12619-70-4, Cyclodextrin 12633-72-6, Amphotericin 15687-27-1, Ibuprofen 18559-94-9, Albuterol 18656-38-7, DMPC 21361-93-3 25104-18-1, Poly(L-lysine) 25191-17-7, Poly(L-alanine) 25213-34-7, Poly(L-alanine) 25301-02-4, Tyloxapol 25322-68-3, Polyethylene glycol 25718-94-9, Polyglycine 25734-27-4, Polyglycine 26009-03-0, Polyglycolide 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26202-08-4, Polyglycolide 26680-10-4, Polylactide 32986-56-4, Tobramycin 33069-62-4, Taxol 37189-22-3, Starch methyl ether 37353-59-6, Hydroxymethyl cellulose 37517-28-5, Amikacin 38000-06-5, Poly(L-lysine) 41017-85-0 43229-80-7, Formoterol fumarate 51293-66-4 51333-22-3, Budesonide 61230-46-4 80474-14-2, Fluticasone **propionate** 93107-08-5, Ciprofloxacin hydrochloride 94749-08-3, Salmeterol xinafoate 95188-93-5 106392-12-5, Poloxamer 110617-70-4, Poloxamine 114466-38-5, Sermorelin acetate 143831-71-4, Pulmozyme 352466-80-9, Tobramycin nitrate 373598-27-7 373598-29-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable metal ion-**lipid** powd. pharmaceutical compns.)
IT **9004-10-8, Insulin**, biological studies **9004-54-0**
, **Dextran**, biological studies **9005-80-5**,
Inulin 9042-14-2, Dextran sulfate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable metal ion-**lipid** powd. pharmaceutical compns.)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-80-5 HCAPLUS
CN Inulin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9042-14-2 HCAPLUS
CN Dextran, hydrogen sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-54-0
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S



L95 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN **2000:841932** HCAPLUS
DN **133:362265**
TI Method for increasing **propionate** in the **gastro-**
intestinal tract
IN **Jann, Alfred; Arrigoni, Eva; Rochat, Florence**
; Schmid, Daniel; Bauche, Anne
PA Societe des Produits **Nestle** S. A., Switz.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A23L001-054
ICS A23L001-308; A23L001-30
CC 18-4 (Animal **Nutrition**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000070964	A1	20001130	WO 2000-EP4744	20000519

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1060673 A1 20001220 EP 1999-109916 19990520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI EP 1999-109916 A 19990520

AB A method for selectively increasing the prodn. of **propionate** in the **gastro-intestinal tract** of a mammal. The method includes the step of enterally administering to the mammal a nutritional compn. which contains **dextran**. Increasing the **propionate** prodn. results in decreased blood **cholesterol** levels, decreased blood **triglyceride** levels, decreased very **low d. lipoprotein** levels, increased **high d. lipoprotein** levels, and increased **insulin** sensitivity.

ST digestive tract **propionate** diet **dextran; lipid** blood digestive tract **propionate** diet **dextran;** lipoprotein blood digestive tract **propionate** diet **dextran; cholesterol** blood digestive tract **propionate** diet **dextran; insulin** sensitivity digestive tract **propionate** diet **dextran**

IT **Lipoproteins**
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(**high-d.**; method for increasing **propionate** in the gastrointestinal tract)

IT **Anticholesteremic** agents
Digestive tract content
(method for increasing **propionate** in the gastrointestinal tract)

IT Glycerides, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(method for increasing **propionate** in the gastrointestinal tract)

IT **Fructooligosaccharides**
Galactooligosaccharides
Lipids, biological studies
Xylooligosaccharides
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for increasing **propionate** in the gastrointestinal tract)

IT **Fatty acids**, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monounsatd.; method for increasing **propionate** in the gastrointestinal tract)

IT **Lipoproteins**
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(**very-low-d.**; method for increasing **propionate** in the gastrointestinal tract)

IT **57-88-5**, Cholest-5-en-3-ol (3.beta.)-, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(blood; method for increasing **propionate** in the gastrointestinal tract)

IT **79-09-4**, **Propionic acid**, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(method for increasing **propionate** in the gastrointestinal tract)

IT **9004-10-8**, **Insulin**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(method for increasing **propionate** in the gastrointestinal tract)

IT **9004-54-0**, **Dextran**, biological studies **9005-80-5**, **Inulin** 187112-48-7, Raftilose
RL: **FFD (Food or feed use)**; THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for increasing **propionate** in the gastrointestinal tract)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; PATENT ABSTRACTS OF JAPAN 1986, V010(043), PC-329
(2) Fisons; EP 0153013 A 1985 HCAPLUS
(3) Hayashibara; EP 0382355 A 1990 HCAPLUS
(4) MC Cormick, D; ANNUAL REVIEWS P117
(5) Meitou Sangyo Kk; JP 60190717 A 1985 HCAPLUS
(6) Nestle; EP 0881283 A 1998 HCAPLUS
(7) Southgate, D; Dietary Fibre:Chemical and biological Aspects 1990, P340

IT **57-88-5**, Cholest-5-en-3-ol (3.beta.)-, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(blood; method for increasing **propionate** in the gastrointestinal tract)

RN 57-88-5 HCAPLUS
CN Cholest-5-en-3-ol (3.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **79-09-4**, **Propionic acid**, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(method for increasing **propionate** in the gastrointestinal tract)

RN 79-09-4 HCAPLUS

CN Propanoic acid (9CI) (CA INDEX NAME)



IT **9004-10-8, Insulin**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(method for increasing **propionate** in the gastrointestinal tract)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **9004-54-0, Dextran**, biological studies **9005-80-5, Inulin**
RL: **FFD (Food or feed use)**; THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for increasing **propionate** in the gastrointestinal tract)
RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-80-5 HCAPLUS
CN Inulin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN **1993:154578** HCAPLUS
DN **118:154578**
TI Prolonged-release oral pharmaceutical forms containing active substances having a solubility dependent upon the pH value
IN Conte, Ubaldo; Giunchedi, Paolo
PA L.C. Pharchem Ltd., Cyprus
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-16
ICS A61K009-20
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9300889	A1	19930121	WO 1992-EP1503	19920703
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9222293	A1	19930211	AU 1992-22293	19920703
	CN 1082888	A	19940302	CN 1992-111078	19920824
PRAI	IT 1991-MI1880		19910708		
	WO 1992-EP1503		19920703		

AB Oral formulations comprise a weakly-basic drug (dipyridamole, cinnarizine, ketanserin) a swellable polymer and a **gastroresistant** polymer, carried in a gellable hydrophilic or lipophilic matrix. The swellable polymer is crosslinked Na CMC or PVC, carboxymethylstarch, PVA, etc. The **gastroresistant** polymer is a cellulose deriv. or acrylic polymer.

Pellets were made of dipyridamole 50, cellulose acetate trimellitate 100, and crosslinked Na CMC 50 g. the pellets were labeled with hydroxypropylmethyl cellulose, Mg stearate and colloidal silica. The formulations release the drug at the same rate in both **gastric** and enteric environments.

ST oral drug sustained release **gastric** enteral

IT Acrylic polymers, biological studies
Zeins
RL: BIOL (Biological study)
(oral drug formulations contg., **gastro-** and entero-sol.)

IT Pharmaceutical dosage forms
(oral, sustained-release, **gastro-** and entero-sol.)

IT 9002-89-5 9003-39-8D, Polyvinylpyrrolidone, crosslinked 9004-32-4D, Sodium carboxymethylcellulose, crosslinked 9004-34-6D, Cellulose, derivs. 9004-38-0, Cellulose acetate phthalate 9004-39-1, Cellulose acetate **propionate 9004-54-0D, Dextran,** derivs. 9005-25-8D, Starch, derivs. 9012-72-0D, Glucan, derivs. 9057-06-1, Carboxymethyl starch 52907-01-4, Cellulose acetate trimellitate 65405-55-2, Potassium methacrylate-divinylbenzene copolymer
RL: BIOL (Biological study)
(oral drug formulations contg., **gastro-** and entero-sol.)

IT 58-32-2, Dipyridamole 298-57-7, Cinnarizine 74050-98-9, Ketanserin
RL: BIOL (Biological study)
(oral formulations contg., **gastro-** and entero-sol.)

IT **9004-54-0D, Dextran,** derivs.
RL: BIOL (Biological study)
(oral drug formulations contg., **gastro-** and entero-sol.)

RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L95 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
AN **1966:414823** HCAPLUS
DN **65:14823**
OREF 65:2782d-g
TI Disturbance of the fatty acid metabolism of arteriosclerosis and its treatment
AU Aizawa, Toyozo; Goto, Yuichiro; Katayama, Tetsuji; Nakamura, Haruo; Hori, Sadaaki; Tatsuzawa, Yasushi
CS Keio Univ., Tokyo
SO Proc. Asian-Pacific Congr. Cardiol., 3rd, Kyoto (1964), (1), 611-15
DT Journal
LA English
CC 66 (Mammalian Pathological Biochemistry)
AB **Cholesterol** level and fatty acid (FA) compn. in plasma was not changed appreciably by age or sex in the normal group under 39 years old. A slightly higher percentage of linoleic acid (I) was observed in women. In normal persons over 40, there was no signifcant change in either **cholesterol** or FA compn. due to age or sex. Hypertensive patients showed slightly higher palmitic acid (II) and oleic acid (III) concns., with I slightly lower than normal. Arteriosclerotics showed a significant increase in II and III, and a significant decrease in I. **Cholesterol** esters had a higher percentage of I in normal young women than in men. Neutral fat, phospholipid, and nonesterified FA in arteriosclerotics showed higher II and III with lower I content than normal. Various **hypocholesterolemic** agents were tested for alteration of the plasma FA compn. MER-29 (an inhibitor of **cholesterol** synthesis), TBF-43 (a synthetic thyroxine deriv.), and atromid decreased the **cholesterol** level markedly, but had no effect on un balanced FA compn. Ethylnandrol, p-tolyl methyl carbinol, neomycin, **dextran** sulfate, and pyridoxal phosphate decreased the **cholesterol** slightly, but did not improve the FA compn. Nicotinic

acid reduced **cholesterol**, but increased II and III while decreasing I. Ateroid (a heparinoid) had no effect on **cholesterol** or FA compn. .alpha.-Tocopherol decreased **cholesterol** only slightly, but improved the FA compn. slightly. 3-Deoxyesterone decreased **cholesterol** and slightly improved the FA compn. Et linoleate was administered to 12 patients and reduced **cholesterol** and neutral fat, and improved the FA compn. of **cholesterol** ester, neutral fat, and phospholipid. The percentage of I increased moderately. The FA pattern in arteriosclerotic patients would be improved if **hypocholesterolemic** agents were administered with I.

IT Arteriosclerosis
(fatty acid metabolism in, therapy and)
IT Blood pressure
(high, fatty acid metabolism in, arteriosclerosis and)
IT Fats
(in blood plasma in arteriosclerosis, therapy and)
IT Phospholipids
(in blood plasma, in arteriosclerosis, therapy and)
IT Blood plasma
(lincomycin in, milk and)
IT Fatty acids
(metabolism of, in arteriosclerosis, therapy and)
IT 2,8-dimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-
(fatty acid metabolism in arteriosclerosis)
IT **Cholesterol**, esters of
(in atherosclerosis, linoleic acid in)
IT **Cholesterol**, esters of
(in blood plasma in arteriosclerosis, therapy and)
IT Blood corpuscles, red.
(linoleic acid in, in atherosclerosis)
IT 53-45-2, Estra-1,3,5(10)-trien-17-one 54-47-7, Pyridoxal, 5-phosphate 78-41-1, Ethanol, 2-(p-chlorophenyl)-1-[p-[2-(diethylamino)ethoxy]phenyl]-1-p-tolyl- 536-50-5, Benzyl alcohol, p,.alpha.-dimethyl- 544-35-4, Linoleic acid, ethyl ester 637-07-0, **Propionic acid**, 2-(p-chlorophenoxy)-2-methyl-, ethyl ester 965-90-2, Ethylnandrol 1160-36-7, Benzoic acid, 4-(4-acetyl-3-iodophenoxy)-3,5-diiodo- 1404-04-2, Neomycins 9010-06-4, Ateroid
(fatty acid metabolism in arteriosclerosis after treatment with)
IT **57-88-5, Cholesterol** 60-33-3, Linoleic acid
(in blood plasma, in arteriosclerosis, therapy and)
IT 59-67-6, Nicotinic acid
(in fatty acid metabolism, in arteriosclerosis)
IT 57-10-3, Palmitic acid 112-80-1, Oleic acid
(metabolism of, in arteriosclerosis, therapy and)
IT **9004-54-0, Dextrans**
(sulfates, fatty acid metabolism in arteriosclerosis after treatment with)
IT **57-88-5, Cholesterol**
(in blood plasma, in arteriosclerosis, therapy and)
RN 57-88-5 HCAPLUS
CN Cholest-5-en-3-ol (3.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **9004-54-0, Dextrans**
(sulfates, fatty acid metabolism in arteriosclerosis after treatment with)
RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> fil medline
FILE 'MEDLINE' ENTERED AT 08:58:41 ON 14 NOV 2002

FILE LAST UPDATED: 13 NOV 2002 (20021113/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

If you received SDI results from MEDLINE on October 8, 2002, these may have included old POPLINE data and in some cases duplicate abstracts. For further information on this situation, please visit NLM at: http://www.nlm.nih.gov/pubs/techbull/so02/so02_popline.html

To correct this problem, CAS will remove the POPLINE records from the MEDLINE file and process the SDI run dated October 8, 2002 again.

Customers who received SDI results via email or hard copy prints on October 8, 2002 will not be charged for this SDI run. If you received your update online and displayed answers, you may request a credit by contacting the CAS Help Desk at 1-800-848-6533 in North America or 614-447-3698 worldwide, or via email to help@cas.org

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L112 ANSWER 1 OF 2 MEDLINE
AN **95017698** MEDLINE
DN **95017698** PubMed ID: **7523661**
TI Functional role of bicarbonate in **propionate** transport across guinea-pig isolated caecum and proximal colon.
AU von Engelhardt W; Gros G; Burmester M; Hansen K; Becker G; Rechkemmer G
CS Department of Physiology, School of Veterinary Medicine, Hannover, Germany.
SO JOURNAL OF PHYSIOLOGY, (1994 Jun 1) 477 (Pt 2) 365-71.
Journal code: 0266262. ISSN: 0022-3751.

CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199411
ED Entered STN: 19941222
Last Updated on STN: 19960129
Entered Medline: 19941110
AB 1. Unidirectional fluxes of **propionate** across isolated epithelia from the guinea-pig caecum and proximal colon were measured under short-circuit current conditions. In the caecum and proximal colon the serosal-to-mucosal **propionate** flux (JPrsm) was higher than mucosal-to-serosal flux (JPrms), resulting in a net secretory flux of **propionate**. 2. HCO3(-)-CO2-free solution reduced JPrms in the caecum and proximal colon markedly; JPrsm was not (caecum) or little (proximal colon) affected. The subsequent addition of acetazolamide caused a further decrease in JPrms in the proximal colon, but not in the caecum. 3. In HCO3(-)-containing solutions acetazolamide or ethoxzolamide inhibited JPrms; JPrsm was not affected. A macromolecular carbonic anhydrase inhibitor, prontosil-**dextran**, had no effect on **propionate** fluxes, indicating that the intracellular carbonic anhydrase is of importance for short-chain fatty acid transport. 4. Subsequent to carbonic anhydrase inhibition, mucosal addition of amiloride caused a slight further decrease of JPrms in the caecum and proximal colon; JPrsm was not affected. 5. Results support the view that a considerable proportion of short-chain fatty acids (SCFAs) is absorbed via a SCFA(-)-HCO3- exchange.
CT Check Tags: Animal; Male; Support, Non-U.S. Gov't
Acetazolamide: PD, pharmacology
*Bicarbonates: ME, metabolism
Carbonic Anhydrases: ME, metabolism
Cecum: DE, drug effects
***Cecum: ME, metabolism**
Colon: DE, drug effects
***Colon: ME, metabolism**
Dextrans: PD, pharmacology
Ethoxzolamide: PD, pharmacology
Guinea Pigs
Intestinal Mucosa: DE, drug effects
***Intestinal Mucosa: ME, metabolism**
Ion Transport: DE, drug effects
***Propionates: ME, metabolism**
p-Aminoazobenzene: AA, analogs & derivatives
p-Aminoazobenzene: PD, pharmacology
RN 103-12-8 (sulfamidochrysoidine); 452-35-7 (Ethoxzolamide); 59-66-5 (Acetazolamide); 60-09-3 (p-Aminoazobenzene); **9004-54-0 (Dextrans)**
CN 0 (Bicarbonates); **0 (Propionates)**; EC 4.2.1.1 (Carbonic Anhydrases)

L112 ANSWER 2 OF 2 MEDLINE
AN **71234310** MEDLINE
DN **71234310** PubMed ID: **4933388**
TI Combined use of clofibrate and cholestyramine or DEAE sephadex in hypercholesterolaemia.
AU Howard A N; Hyams D E
SO BRITISH MEDICAL JOURNAL, (1971 Jul 3) 3 (765) 25-7.
Journal code: 0372673. ISSN: 0007-1447.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Abridged Index Medicus Journals; Priority Journals

EM 197108
ED Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19710821
CT Check Tags: Comparative Study; Human
*Anticholesteremic Agents: TU, therapeutic use
Cholesterol: BL, blood
Cholestyramine: AE, adverse effects
*Cholestyramine: TU, therapeutic use
Clinical Trials
Clofibrate: TU, therapeutic use
Constipation: CI, chemically induced
***Dextrans: TU, therapeutic use**
Drug Synergism
***Hypercholesterolemia: DT, drug therapy**
***Propionates: TU, therapeutic use**
RN 11041-12-6 (Cholestyramine); 57-88-5 (Cholesterol); 637-07-0 (Clofibrate); **9004-54-0 (Dextrans)**
CN 0 (Anticholesteremic Agents); **0 (Propionates)**

=> fil wpix
FILE 'WPIX' ENTERED AT 09:11:28 ON 14 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 13 NOV 2002 <20021113/UP>
MOST RECENT DERWENT UPDATE: 200273 <200273/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE http://www.derwent.com/dwpi/updates/dwpicov/index.html <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d all abeq tech abex tot

L130 ANSWER 1 OF 3 WPIX (C) 2002 THOMSON DERWENT
AN 2001-049855 [06] WPIX
DNC C2001-013691
TI Use of **dextran** to selectively increase mammalian gastrointestinal **propionate** production, useful for nutritional compositions e.g. for reducing blood cholesterol levels.
DC B04 D13
IN ARRIGONI, E; JANN, A; ROCHAT, F; SCHMID, D; BAUCHE, A
PA (NEST) SOC PROD NESTLE SA
CYC 92
PI WO 2000070964 A1 20001130 (200106)* EN 17p A23L001-054 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS

LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
EP 1060673 A1 20001220 (200106) EN A23L001-054 <--
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
AU 2000059689 A 20001212 (200115) A23L001-054 <--
ADT WO 2000070964 A1 WO 2000-EP4744 20000519; EP 1060673 A1 EP 1999-109916 19990520; AU 2000059689 A AU 2000-59689 20000519
FDT AU 2000059689 A Based on WO 200070964
PRAI EP 1999-109916 19990520
IC ICM **A23L001-054**
ICS **A23L001-30; A23L001-308**
AB WO 200070964 A UPAB: 20010126
NOVELTY - The use of **dextran** in nutritional compositions that selectively increase **propionate** production in the mammalian gastrointestinal tract, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the use of **dextran** in nutritional compositions that decrease mammalian blood levels of cholesterol, triglycerides, very low density lipoproteins, high density lipoproteins, and that decrease insulin sensitivity.
ACTIVITY - Anorectic; antilipemic.
MECHANISM OF ACTION - Dietary supplement; blood-lipid reducer; insulin desensitizer. **Dextran** is a substrate for fermentation by gut commensal micro-organisms. The fermentation produces **propionate** that has the lipid-lowering and insulin-desensitizing properties. Four volunteers in a double-blind cross-over study to evaluate the effect of **dextran** on **propionate** production. This was determined through measuring fecal concentrations **propionic acid**. Giving **Dextran** T2000 (15 g) acutely increased the **propionic acid** concentration in the test group by 3.43 mM compared with the control. A chronic dose of 10 g/day for a week gave an increase of 24 micro M/g dry feces in the treatment group and a decrease of 5.7 micro M/g dry feces in the control group.
USE - The **dextran** is useful for making nutritional compositions that increase **propionate** production in the mammalian gastrointestinal tract thereby decreased blood levels of cholesterol, triglycerides, very low density lipoproteins, high density lipoproteins, and decreasing insulin sensitivity.
ADVANTAGE - **Dextran** produces more **propionate** than other non-digestible polysaccharides in the mammalian gastrointestinal tract.
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B01-D02; **B04-C02C**; B04-C02X; B10-G02; B12-M07; B14-D01D; **B14-E12; B14-F06; D03-H01T2**
TECH UPTX: 20010126
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The **Dextran** preferably has a molecular weight of more than 500000. The composition optionally comprises insulin, fructo-, galacto- or xylo-oligosaccharides, or mixtures thereof and a lipid source rich in monounsaturated fatty acids that is also low in saturated fatty acids.
ABEX
ADMINISTRATION - Taken orally as a nutritional composition or as a food additive. The dose of dextran is 2-15 g/day.

L130 ANSWER 2 OF 3 WPIX (C) 2002 THOMSON DERWENT
AN **1967-06286G** [00] WPIX
TI Calcium salts of carboxymethyl **dextrans** antihypocalcaemic.
DC B00 C00
PA (PHAA) AKTIEBOLAGET PHARMACIA
CYC 1

PI US 3262847 A (196800)*
PRAI US 1962-240167 19621126
AB US 3262847 A UPAB: 19930831
Water-soluble calcium salts (I) of **carboxymethyldextran** having, on average, 0.5-2.0 carboxymethyl gps. per anhydroglucopyranosic unit, the av. m.wt. of said **dextrans** being is not > 20,000 and pref. 2000-10,000, esp. 2000-5000.
Restricted to (i) method of treating cattle delivery paresis with aq. injectable soln. contng. I (MW **dextran** 2000-5000) and (ii) compn. comprising I (MW **dextran** 2000-5000) together with Ca **propionate** in an aq. injectable soln.
Treatment of Ca deficiency conditions, esp. cattle delivery paresis. Administration is generally by injecting an aq. soln. of I. For treating cattle delivery paresis an aq. soln. contng. both I and Ca **propionate** (II) is pref. I provides a sustained action, whereas II provides the immediate response that is required. This favourable combination of effects is attained without risk to the heart, which may occur if II is used alone.
FS CPI
FA AB
MC CPI: B04-C02; B05-A01B; B12-L09; C04-C02; C05-A01B; C12-L09

L130 ANSWER 3 OF 3 WPIX (C) 2002 THOMSON DERWENT
AN **1966-22170F** [00] WPIX
TI Calcium salts of carboxymethyl **dextrans** antihypocalcaemic.
DC B00 C00
PA (PHAA) AKTIEBOLAGET PHARMACIA
CYC 1
PI US 3262847 A (196800)*
PRAI US 1962-240167 19621126
AB US 3262847 A UPAB: 19930831
Water-soluble calcium salts (I) of **carboxymethyldextran** having, on average, 0.5-2.0 carboxymethyl gps. per anhydroglucopyranosic unit, the av. m.wt. of said **dextrans** being is no > 20,000 and pref. 2000-10,000, esp. 2000-5000.
Restricted to (I) method of treating cattle delivery paresis with aq. injectable soln. contng. I (MW **dextran** 2000-5000) and (ii) compn. comprising I (MW **dextran** 2000-5000) together with Ca **propionate** in an aq. injectable soln.
Treatment of Ca deficiency conditions, esp. cattle delivery paresis. Administration is generally by injecting an aq. soln. of I. For treating cattle delivery paresis an aq. soln. contng. both I and Ca **propionate** (II) is pref. I provides a sustained action, whereas II provides the immediate response that is required. This favourable combination of effects is attained without risk to the heart, which may occur if II is used alone.
FS CPI
FA AB
MC CPI: B04-C02; B05-A01B; B12-L09; C04-C02; C05-A01B; C12-L09

=> fil frosti
FILE 'FROSTI' ENTERED AT 09:15:19 ON 14 NOV 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE LAST UPDATED: 12 NOV 2002 <20021112/UP>
FILE COVERS 1972 TO DATE.

=> d all tot

L146 ANSWER 1 OF 2 FROSTI COPYRIGHT 2002 LFRA
AN 544888 FROSTI

TI Method for increasing the production of **propionate** in the gastro-intestinal tract.
IN Jann A.; Arrigoni E.; Rochat F.; Schmid D.
PA Societe des Produits Nestle SA
SO European Patent Application
PI EP 1060673 A1
AI 19990520
DT Patent
LA English
SL English
AB A method for increasing the production of **propionate** in the gastro-intestinal tract of mammals is described. **Dextran** may be added to food products to increase the production of **propionate** in the GI tract. Patient compliance is enhanced when the **dextran** is added to a convenience food product. Increasing **propionate** levels decreases blood triglyceride and very-low-density lipoprotein levels, whilst enhancing high-density lipoproteins and insulin sensitivity.
SH FUNCTIONAL FOODS
CT BLOOD LIPIDS; BLOOD SERUM; **DEXTRAN**; DIGESTIVE AIDS; DIGESTIVE DISORDERS; EUROPEAN PATENT; FUNCTIONAL FOODS; HIGH DENSITY LIPOPROTEINS; INSULIN SENSITIVITY; LIPOPROTEINS; LOW DENSITY LIPOPROTEINS; PATENT; POLYSACCHARIDES; **PROPIONATES**; PROTEINS; TRIGLYCERIDES
DED 16 Feb 2001

L146 ANSWER 2 OF 2 FROSTI COPYRIGHT 2002 LFRA
AN 543990 FROSTI
TI Method for increasing **propionate** in the gastro-intestinal tract.
IN Jann A.; Arrigoni E.; Rochat F.; Schmid D.; Bauche A.
PA Societe des Produits Nestle SA
SO PCT Patent Application
PI WO 2000070964 A1 20001130
AI 20000519
PRAI European Patent Office 19990520
NTE 20001130
DT Patent
LA English
SL English
AB A method is given for increasing the production of **propionate** in the gastrointestinal tract by enterally administering a nutritional composition containing **dextran**. This can also decrease blood triglyceride levels and low-density lipoprotein levels.
SH FUNCTIONAL FOODS
CT **DEXTRAN**; DIETARY SUPPLEMENTS; FUNCTIONAL FOODS; GASTROINTESTINAL TRACT; PATENT; PCT PATENT; POLYSACCHARIDES; PREBIOTICS; **PROPIONATES**
DED 7 Feb 2001

=> d his

(FILE 'HOME' ENTERED AT 07:28:54 ON 14 NOV 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 07:29:05 ON 14 NOV 2002
E PROPIONIC ACID/CN
L1 1 S E3
E PROPIONATE/CN
L2 1 S E3
E DEXTRAN/CN
L3 1 S E3
L4 2 S L1,L2

```
             SEL RN
L5         1416 S E1-E2/CRN
L6          929 S L5 NOT (MNS OR MXS OR IDS OR PMS OR AYS OR CCS)/CI
L7          530 S L6 NOT COMPD
L8          331 S L7 NOT SALT
L9          199 S L7 NOT L8
L10          15 S L9 AND NR>=1
L11         184 S L9 NOT L10
L12         186 S L4,L11
             SEL RN L3
L13         931 S E3/CRN
L14        1132 S DEXTRAN
L15        1134 S L13,L14
L16        1133 S L15 NOT L3
             E INULIN/CN
L17             1 S E3
               E FRUCTOSE/CN
L18             2 S E3
L19             1 S L-FRUCTOSE/CN
               E GALACTOSE/CN
L20             2 S E3
L21             1 S L-GALACTOSE/CN
               E XYLOSE/CN
L22             2 S E3
L23             1 S L-XYLOSE/CN

     FILE 'HCAPLUS' ENTERED AT 07:47:22 ON 14 NOV 2002
L24         19794 S L4
L25          2929 S L11
L26         68956 S PROPIONIC ACID OR PROPIONATE
L27          5679 S PROPANOIC ACID
L28         78352 S L24-L27
L29         11735 S L3
L30          7546 S L16
L31         30359 S DEXTRAN
L32         31947 S ?DEXTRAN?
L33         33493 S L29-L32
L34           158 S L28 AND L33

     FILE 'REGISTRY' ENTERED AT 07:50:44 ON 14 NOV 2002
L35             1 S CHOLESTEROL/CN

     FILE 'HCAPLUS' ENTERED AT 07:50:48 ON 14 NOV 2002
L36         85119 S L35
L37        153391 S ?CHOLESTER?
L38         10311 S HYPERLIPID? OR HYPERLIPEM? OR HYPERLIPAEM?
L39         28640 S TRIGLYER? OR VLDL OR HDL OR LIPOPROTEIN(L)(VLD OR HD OR VERY

     FILE 'REGISTRY' ENTERED AT 07:53:24 ON 14 NOV 2002
L40             1 S INSULIN/CN
L41          6338 S INSULIN NOT L40

     FILE 'HCAPLUS' ENTERED AT 07:53:33 ON 14 NOV 2002
L42        101061 S L40 OR L41
L43        148034 S ?INSULIN?

     FILE 'REGISTRY' ENTERED AT 07:53:52 ON 14 NOV 2002
L44             2 S GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 07:53:58 ON 14 NOV 2002
L45        133720 S L44
L46        342761 S GLUCOSE
L47            35 S L34 AND L36-L39,L42,L43,L45,L46
```

```
L48       33393 S LIPOPROTEIN(L)(VERY ()(LOW DENSITY OR LOW DEN OR L DENSITY OR
L49           1 S L34 AND L48
L50          35 S L47,L49
L51           2 S L3 (L) FFD/RL AND L50
L52           2 S L50 AND NUTRI?/SC,SX
L53          12 S L50 AND (L17-L23 OR INULIN OR ?FRUCTO? OR ?GALACTO? OR ?XYLO?
                E SACCHARIDE/CT
                E E4+ALL
L54        1628 S E1
                E E3+ALL
L55        7563 S E3
                E E4+ALL
                E E4+ALL
L56       26460 S E4,E3,E18,E37,E38,E64
                E E5+ALL
                E E5+ALL
L57       39306 S E3
L58          12 S L50 AND L54-L57
L59          20 S L51-L53,L58
L60           3 S L59 AND FATTY ACID
L61           3 S L59 AND LIPID
L62           4 S L60,L61
                SEL DN AN 2 3
L63           2 S L62 AND E1-E6
L64          31 S L50 NOT L62
                SEL DN AN 4 31
L65           2 S L64 AND E7-E12
L66           4 S L63,L65 AND L24-L34,L36-L39,L42,L43,L45-L65
L67           3 S L34 AND TRIGLYCER?
L68           1 S L67 AND GASTRO INTESTINAL TRACT
L69           4 S L66,L68
                E JANN A/AU
L70          13 S E3,E5
                E ARRIGONI E/AU
L71         117 S E3,E8,E9
                E ROCHAT F/AU
L72          19 S E3-E5,E7
                E SCHMID D/AU
L73         160 S E3-E15
                E BAUCHE A/AU
L74           4 S E3,E5
                E NESTLE/PA,CS
L75        2322 S E3,E4
L76        2325 S NESTLE?/PA,CS
L77           1 S L50 AND L70-L76
L78           4 S L69,L77
L79        4165 S L28 AND (GASTROINTESTIN? OR GASTRO INTESTIN? OR ?INTESTIN? OR
                E GASTROINTESTIN/CT
                E E30+ALL
                E E2+ALL
L80      551727 S E3+NT
L81        4420 S E102+NT OR E106+NT
                E GASTROINTESTIN/CT
                E E9+ALL
L82        3886 S E2
                E ANTICHOLESTEROL/CT
                E E4+ALL
                E E2+ALL
L83        8108 S E5,E6,E4+NT
L84        3567 S L28 AND L80-L83
L85        6169 S L79,L84
L86         319 S L85 AND CARBOHYDRATE?/SC,SX,CW
L87        2153 S L28 AND L36-L39,L42,L43
```

```
L88          74 S L87 AND CARBOHYDRATE?/SC,SX,CW
L89          12 S L86,L87 AND L33
L90           3 S L89 AND L78
L91           9 S L89 NOT L90
L92          34 S L85,L87 AND L33
L93          19 S L92 NOT L50
                SEL DN AN 12
L94           1 S E1-E3 AND L93
L95           5 S L78,L90,L94
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 08:34:16 ON 14 NOV 2002
L96           8 S E4-E11

     FILE 'REGISTRY' ENTERED AT 08:34:42 ON 14 NOV 2002

     FILE 'HCAPLUS' ENTERED AT 08:34:58 ON 14 NOV 2002

     FILE 'MEDLINE' ENTERED AT 08:35:21 ON 14 NOV 2002
L97       18017 S L28
                E PROPIONATE/CT
                E E5+ALL
L98        5614 S E21/CT,CN
L99        3011 S E26/CT,CN
L100      18017 S L97-L99
L101      15674 S L3
                E DEXTRAN/CT
                E E3+ALL
                E E2+ALL
L102      14655 S E21/CT,CN
L103         19 S L100 AND L101,L102
L104         41 S L100 AND ?DEXTRAN?
L105         41 S L103,L104
                E 34 38 40 AB
L106          9 S L105 AND (A3. OR C6.)/CT
L107          1 S L105 AND C18./CT
L108          9 S L106,L107
L109          8 S L108 NOT DEXTRAN SODIUM SULFATE
L110          7 S L109 NOT DEXTRAN SULFATE SODIUM
L111          6 S L110 NOT DEXTRAN SULFATE
                SEL DN AN 2 6
L112          2 S L111 AND E1-E6

     FILE 'MEDLINE' ENTERED AT 08:58:41 ON 14 NOV 2002

     FILE 'WPIX' ENTERED AT 08:58:53 ON 14 NOV 2002
L113      16697 S L26 OR L27 OR R00445/DCN OR 0445/DRN
L114        113 S C07C053-122/IC,ICM,ICS,ICA,ICI
L115      16747 S L113,L114
L116      14003 S ?DEXTRAN? OR V721/M0,M1,M2,M3,M4,M5,M6 OR R01857/DCN OR 1857/
L117        104 S L115 AND L116
L118          5 S L117 AND A23?/IC,ICM,ICS,ICA,ICI
L119          2 S L117 AND D03-H01T?/MC
L120          5 S L117 AND (B14-F06 OR C14-F06 OR B12-H03 OR C12-H03 OR B14-E12
L121          5 S L117 AND (P814 OR P816)/M0,M1,M2,M3,M4,M5,M6
                E R16573+ALL/DCN
L122        462 S E1
                E R01851+ALL/DCN
                E R06675+ALL/DCN
L123         10 S L122 AND L115
L124          0 S L123 NOT L117
L125         10 S L118-L121
L126          1 S L123 AND L125
```

```
L127          9 S L123 NOT L126
L128         85 S L117,L123 NOT L118-L121,L123-L127
                SEL DN AN 83 84
L129          2 S L128 AND E1-E2
L130          3 S L126,L129 AND L113-L129

     FILE 'WPIX' ENTERED AT 09:11:28 ON 14 NOV 2002

     FILE 'FSTA' ENTERED AT 09:11:42 ON 14 NOV 2002
L131       1823 S L26 OR L27
L132        875 S DEXTRAN OR OLIGODEXTRAN
                E DEXTRAN/CT
                E E3+ALL
L133        205 S E5
                E PROPION/CT
L134         40 S E11,E21
                E E43+ALL
L135        407 S E5
                E PROPANOIC/CT
L136          1 S E4
L137          2 S L131,L134-L136 AND L132,L133

     FILE 'FROSTI' ENTERED AT 09:13:31 ON 14 NOV 2002
L138       1113 S L131
                E PROPANOIC/CT
L139          1 S E4
                E PROPIONIC/CT
L140        397 S E5
                E PROPIONATE/CT
                E E4+ALL
L141        106 S E1
L142        397 S E2+NT
L143       1113 S L138-L142
L144        517 S L132
                E DEXTRAN/CT
                E E3+ALL
L145        263 S E4
L146          2 S L143 AND L144,L145

     FILE 'FROSTI' ENTERED AT 09:15:19 ON 14 NOV 2002
```